Apps

Stoke, Biogen report four-year zorevunersen data showing sustained seizure control — 1dAt the European Epilepsy Congress in Athens, Stoke Therapeutics and Biogen presented four-year data from Phase 1/2a open-label extensions showing sustained cognitive and behavioral improvements plus durable seizure reductions for zorevunersen in Dravet syndrome, with results supporting ongoing Phase 3 EMPEROR and an anticipated 2027 readout. Separately, GRIN Therapeutics announced its on-site participation at the congress to discuss progress on GRIN-related neurodevelopmental disorders and potential collaborations, underscoring ongoing activity in epilepsy-focused biotech development.

Sam Okafor Good to see multiple companies like GRIN Therapeutics also active at this congress, feels like real momentum building in the rare epilepsy space.

CEPI funds Bundibugyo Ebola vaccine candidate into clinicHealth — Aug 26, 2026CEPI announced up to $16.5 million to Minapharm/ProBioGen to advance Bundibugyo ebolavirus vaccine into early-stage human trials in Africa, marking the fifth Bundibugyo-specific candidate it backs and aiming to have at least two vaccines reach Emergency Use Authorization and WHO prequalification amid the DRC outbreak. The UN warns the outbreak is the largest and fastest-growing in DRC and seeks about $1.1 billion, while CEPI grapples with a substantial funding shortfall despite borrowing $100 million from existing programs and additional pledges to push vaccine development forward.